Clinical trials: Urinary Incontinence, Urgency-frequency
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects
This study is designed to estimate the effect of fluconazole (200 mg BID for 2 days), a moderate CYP3A4 inhibitor on the pharmacokinetics of a single 8 mg oral dose of fesoterodine in healthy adult subjects.
- Trial name
- NCT00911235
- Testing
- Fesoterodine, fesoterodine plus fluconazole
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Urinary Bladder, Overactive
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
- Trial name
- SCORPIO (NCT00689104)
- Testing
- Mirabegron, Tolterodine
- Where
- 218 sites in Australia, Austria and 28 more
- Volunteers
- 2,336 people
- Sponsor
- Astellas Pharma Inc
Urinary Incontinence
A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.
- Trial name
- VICTOR (NCT00333112)
- Testing
- solifenacin succinate, tamsulosin
- Where
- 74 sites in United States
- Volunteers
- 398 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder
The purpose of this study is to evaluate the change from baseline between the active and sham treatment groups in the treatment of urgency (urinary) incontinence episodes (leaks).
- Trial name
- Beacon (NCT01369485)
- Testing
- (VERV™ System)
- Where
- 14 sites in United States
- Volunteers
- 163 people
- Sponsor
- Ethicon Endo-Surgery
Pelvic Floor Disorders, Anxiety
Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders
The purpose of this proposal is to test a novel behavioral treatment - Unified Protocol Cognitive-Behavior Therapy (UP-CBT)1 - to enhance quality of life in women with pelvic floor disorders.
- Conditions
- Pelvic Floor Disorders, Anxiety, Urinary Urgency, Urinary Incontinence
- Trial name
- NCT03623880
- Testing
- Unified Protocol, Supportive Therapy
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Overactive Bladder, Urinary Frequency
FREEOAB Study for Overactive Bladder
This is a prospective, multicenter study that was conducted to evaluate the safety and efficacy of a novel, closed-loop, continuous-sensing wearable neuromodulation system for Overactive Bladder symptom control.
- Conditions
- Overactive Bladder, Urinary Frequency, Urinary Incontinence, Urge, Urinary Urgency
- Trial name
- NCT04547920
- Testing
- Wearable Bladder Modulation System
- Where
- 9 sites in United States
- Volunteers
- 96 people
- Sponsor
- Avation Medical, Inc.
Urinary Bladder, Overactive
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active…
- Trial name
- TAURUS (NCT00688688)
- Testing
- Mirabegron, Tolterodine
- Where
- 308 sites in United States, Australia and 28 more
- Volunteers
- 2,792 people
- Sponsor
- Astellas Pharma Inc
Urge Incontinence, Urgency-frequency Syndrome
The Effect of Solifenacin Used for Lower Urinary Tract Symptoms on Sexual Function
This study aims to determine whether Solifenacine used for lower urinary tract symptoms improves sexual function and if so does this improvement differs between premenopausal and postmenopausal women.
- Trial name
- NCT05391425
- Testing
- no intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Istanbul University
Urinary Incontinence, Urgency-frequency, Overactive Bladder
InSite for Over Active Bladder
The purposes of this study are: 1. To provide evidence from a randomized controlled trial that InterStim Therapy provides better relief of symptoms of OAB than standard medical treatments in current use. 2.
- Trial name
- InSite - OAB (NCT00547378)
- Testing
- InterStim, Standard Medical Therapy
- Volunteers
- 571 people
- Sponsor
- MedtronicNeuro
Lower Urinary Tract Symptoms, Female Genitourinary Disease
Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women
The goal of this clinical trial is to evaluate whether vaginal 17β-estradiol effectively treats storage symptoms of lower urinary tract symptoms (LUTS) and enhances quality of life.
- Conditions
- Lower Urinary Tract Symptoms, Female Genitourinary Disease, Urinary Stress Incontinence, Urinary Urge Incontinence
- Trial name
- NCT06508944
- Testing
- vaginal 17 beta-estradiol, Behavioral modifications
- Where
- Thailand
- Volunteers
- 86 people
- Sponsor
- Mahidol University
Urinary Incontinence
Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.
- Trial name
- NCT00230789
- Testing
- Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material
- Where
- 51 sites in United States
- Volunteers
- 417 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder, Urinary Incontinence, Urge
Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO
comparing the outcome of low-intensity shock wave therapy (Li-SWT) versus solifenacin on persistent storage symptoms after transurethral surgery for benign prostatic obstruction (BPO)
- Conditions
- Overactive Bladder, Urinary Incontinence, Urge, Urgency-frequency Syndrome, Post Prostatectomy
- Trial name
- NCT04437108
- Testing
- Li-SWT (suprapubic approach), Li-SWT (perineal approach), Li-SWT (combined approach)
- Where
- Egypt
- Volunteers
- 132 people
- Sponsor
- Mansoura University
Overactive Bladder, Urinary Incontinence
The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
This study aims to assess the efficacy of a specialized herbal formula, Urox, versus control over 8 weeks, in a double blind, placebo controlled trial.
- Conditions
- Overactive Bladder, Urinary Incontinence, Urinary Frequency or Urgency Adverse Event, Nocturia
- Trial name
- NCT02396160
- Testing
- Urox
- Volunteers
- 150 people
- Sponsor
- The University of Queensland
Overactive Bladder (OAB), Refractory Overactive Bladder
Cefar URO - Symptomatic Treatment of Overactive Bladder
A Post-Market Prospective Clinical Investigation to collect PMCF data on the safety and performance of the Cefar URO device when using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the…
- Conditions
- Overactive Bladder (OAB), Refractory Overactive Bladder, Urinary Urgency and Frequency
- Trial name
- NCT06659536
- Testing
- Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device
- Where
- France
- Volunteers
- 53 people
- Sponsor
- DJO UK Ltd
Overactive Bladder
Sham Controlled Trial of Rapid Induction Percutaneous Tibial Nerve Stimulation
The aim of this study is to determine the efficacy of an accelerated course for percutaneous tibial nerve stimulation (PTNS) induction to treat overactive bladder symptoms.
- Trial name
- NCT03547518
- Testing
- PTNS treatment
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Corewell Health East
Overactive Bladder (OAB), Overactive Bladder Syndrome
Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study
Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage.
- Trial name
- WoMEN'S (NCT07416968)
- Testing
- Tadalafil 5 mg, Solifenacin 5mg
- Where
- 14 sites in Egypt
- Volunteers
- 480 people
- Sponsor
- Mansoura University
Overactive Bladder
Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder
To investigate the long-term safety, efficacy and pharmacokinetics of KUC-7483 in patients with overactive bladder.
- Trial name
- NCT01003405
- Testing
- KUC-7483
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Urinary Urgency, Urinary Frequency
Efficacy and Safety of Gabapentin in Treating Overactive Bladder
Overactive bladder (OAB) syndrome as defined by International Continence Society is a pathological condition characterized by irritative symptoms: urinary urgency, with or without incontinence, urinary frequency and nocturia.
- Conditions
- Urinary Urgency, Urinary Frequency, Nocturia, Incontinence
- Trial name
- OAB (NCT01486706)
- Testing
- Gabapentin, Solifenacin Succinate
- Where
- Philippines
- Volunteers
- 94 people
- Sponsor
- Michael E. Chua
Overactive Bladder (OAB)
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
To investigate the efficacy and safety of KUC-7483 in overactive bladder patients.
- Trial name
- NCT00742833
- Testing
- KUC-7483
- Where
- 6 sites in Japan
- Volunteers
- 400 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.